Brief: Rafael Pharmaceuticals Receives FDA Fast Track Designation For Cpi-613 For Treatment Of Pancreatic Cancer
10/11/2020 14:11
Nov 10 (Reuters) - Rafael Holdings Inc RFL.N :
* RAFAEL PHARMACEUTICALS RECEIVES FDA FAST TRACK DESIGNATION
FOR
CPI-613® (DEVIMISTAT) FOR THE TREATMENT OF PANCREATIC CANCER
Source text for Eikon: ID:nGNXbGWM7h
Further company coverage: RFL.N
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rafael Holdings
See all newsBrief: Rafael Holdings Announces Topline Results From The Pivotal Phase 3 Transportnpc™ Study Of Trappsol® Cyclo™ In Niemann-Pick Disease Type C (Npc)
Israel expects new air defence orders from Europe due to Russia concerns
Biotech firm Rafael's Q3 net loss narrows; set to submit NDA for Trappsol Cyclo in H2
Rafael Holdings Q2 net loss widens on consolidation of Cyclo Therapeutic's costs
Brief: Rafael Holdings Q2 Net Income USD -6.327 Million